Table 2 Dose-response parameters used in the relative seriality model for the organs at risk included in the optimization [30–33].
Tissue | D50/Gy | γ | s | Endpoint |
|---|---|---|---|---|
PTV1 | 51.0 | 7.5 | - | Control |
PTV2 | 44.0 | 4.0 | - | Control microscopic disease |
PTV3 | 38.0 | 2.0 | - | Control microscopic disease |
Spinal cord | 57.0 | 6.7 | 1.00 | Myelitis necrosis |
Parotids | 46.0 | 1.8 | 0.01 | Xerostomia |
Mandible | 70.3 | 3.8 | 1.00 | Marked limitation of joint function |
Oral cavity | 70.0 | 3.0 | 0.50 | Mucositis |
Lungs | 30.0 | 1.0 | 0.01 | Severe radiation pneumonitis-fibrosis |
Surrounding tissue | 65.0 | 2.8 | 1.00 | Necrosis |